Guys and St. Thomas' Hospital

London SE1 9RT

2 studies enrolling now · 29 studies all time

What they study most

Acute Kidney Injury, Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, Aortic Valve Disorder, Atrial Fibrillation, B-cell Chronic Lymphocytic Leukemia, Carcinoma, Squamous Cell of the Head and Neck, Cardiac Surgery, Crohn Disease, Diabetes Mellitus, Type 1, Essential Thrombocythemia, Gastro-enteropancreatic Neuroendocrine Tumor, Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
• Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT — Recruiting now
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment — Running, not enrolling
• Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT — Running, not enrolling
• Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer — Running, not enrolling
• Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate — Running, not enrolling
• Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) — Completed
• IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC — Completed
• A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer — Completed
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET — Running, not enrolling
• A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer — Running, not enrolling
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults — Completed
• Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial) — Completed
• Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU) — Stopped early
• IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) — Stopped early
• CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF) — Completed
• CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AF — Withdrawn before enrolling
• A Phase 2 Study of RO7490677 In Participants With Myelofibrosis — Completed
• A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy — Completed
• Registry Study for Talimogene Laherparepvec — Completed
• QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery — Stopped early
• A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma — Completed
• Validation Study of ClassIntra® — Completed
• Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers — Completed
• Transcatheter Aortic Valve Intervention-Live Transmission — Completed